Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 3:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Cytochrome P450 (CYP) Substrates Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects

NCT05657613
View directory record Official record
Conditions
Drug Interactions
Interventions
CYP450 Cocktail and Transporter Substrates with Pacritinib, Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib, Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Sep 26, 2026, 3:34 PM EDT
Completed Phase 1 Interventional Results available

A Study of Mirikizumab in Participants With Plaque Psoriasis

NCT03718884
View directory record Official record
Conditions
Psoriasis
Interventions
Drug Cocktail, Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Anaheim, California • DeLand, Florida • High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 28, 2024 · Synced Sep 26, 2026, 3:34 PM EDT
Completed Phase 1 Interventional

Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer

NCT03333824
View directory record Official record
Conditions
Solid Tumours
Interventions
CYP1A2 (caffeine), CYP2C19 (omeprazole), CYP3A (midazolam), Kytril (granisetron), Wee-1 kinase inhibitor AZD1775
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
Bingham Farms, Michigan • Detroit, Michigan • Lebanon, New Hampshire + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2019 · Synced Sep 26, 2026, 3:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate The Effect of T89(Dantonic®)On P450 Enzymes

NCT01473888
View directory record Official record
Conditions
Stable Angina
Interventions
T89(Dantonic)
Drug
Lead sponsor
Tasly Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Nov 7, 2012 · Synced Sep 26, 2026, 3:34 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study

NCT02760615
View directory record Official record
Conditions
Colitis, Ulcerative, Crohn Disease
Interventions
Caffeine, Losartan, Omeprazole, Dextromethorphan, Midazolam, Vedolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
2
States / cities
Cypress, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Sep 26, 2026, 3:34 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

NCT04254783
View directory record Official record
Conditions
Ulcerative Colitis (UC), Crohn's Disease
Interventions
Risankizumab, Cytochrome P450 (CYP) Substrates
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Coronado, California • DeLand, Florida • Margate, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Sep 26, 2026, 3:34 PM EDT
Completed Phase 1 Interventional

A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab

NCT05175352
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Cendakimab, CYP substrates
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Tucson, Arizona • Los Angeles, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Sep 26, 2026, 3:34 PM EDT
Completed Phase 1 Interventional Results available

A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body

NCT02688088
View directory record Official record
Conditions
Neoplasm Metastasis
Interventions
Drug Cocktail, Abemaciclib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
5
States / cities
Denver, Colorado • Indianapolis, Indiana • Fairway, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Sep 26, 2026, 3:34 PM EDT
Completed Early Phase 1 Interventional

Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis

NCT05891119
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Caffeine, Metoprolol, Midazolam, Warfarin, Vitamin K, Omeprazole, Rocatinlimab
Dietary Supplement · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
North Hollywood, California • DeLand, Florida • Hialeah, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 26, 2026, 3:34 PM EDT
Recruiting Phase 4 Interventional

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

NCT07486713
View directory record Official record
Conditions
AML (Acute Myeloid Leukemia), Glioma, Cholangiocarcinoma, Solid Tumor Malignancies
Interventions
Olutasidenib, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Orange, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 26, 2026, 3:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Lazertinib (JNJ-73841937) in Healthy Participants

NCT05076877
View directory record Official record
Conditions
Healthy
Interventions
Lazertinib, Midazolam, Rosuvastatin, Metformin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 26, 2022 · Synced Sep 26, 2026, 3:34 PM EDT
Not yet recruiting Early Phase 1 Interventional

Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study

NCT07389525
View directory record Official record
Conditions
Gastrointestinal Neoplasms, Genitourinary Cancer, Thoracic Cancer, Sarcoma, Melanoma
Interventions
ICI Therapy
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 26, 2026, 3:34 PM EDT
Completed Phase 1 Interventional Results available

A Study of Ixekizumab in Participants With Plaque Psoriasis

NCT02993471
View directory record Official record
Conditions
Psoriasis
Interventions
Drug Cocktail, Ixekizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Anaheim, California • DeLand, Florida • High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2019 · Synced Sep 26, 2026, 3:34 PM EDT
Completed Phase 1 Interventional

Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4

NCT03556592
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Caffeine, Warfarin, Omeprazole, Metoprolol, Midazolam Hydrochloride
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Little Rock, Arkansas • Rogers, Arkansas • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Sep 26, 2026, 3:34 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight

NCT07710768
View directory record Official record
Conditions
Obesity, Overweight
Interventions
UBT251, Cocktail (Warfarin/Caffeine/Midazolam)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 26, 2026, 3:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs As a Means of Predicting Drug-drug Interactions

NCT03234699
View directory record Official record
Conditions
Healthy
Interventions
Cenobamate, midazolam, Warfarin Pill, Omeprazole Pill, Bupropion Pill
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 26, 2026, 3:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants

NCT07223671
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Repotrectinib, Metformin, Digoxin, Rosuvastatin, Bupropion, Flurbiprofen, Omeprazole
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 26, 2026, 3:34 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis

NCT04562116
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Nemolizumab, CYP 450 Substrates
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
North Hollywood, California • Hallandale, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Sep 26, 2026, 3:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study on Effects of BMS-955176 on the Pharmacokinetics of Probe Substrates

NCT02578277
View directory record Official record
Conditions
HIV Infections
Interventions
CYP and transporter probe substrates, BMS-955176, BMS-955176 plus CYP and transporter probe substrates
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Sep 26, 2026, 3:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin

NCT03131973
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
BMS-986195, Methotrexate, Leucovorin, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, Pravastatin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Sep 26, 2026, 3:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Research Study to Investigate How a Study Medicine (NNC9204- 1177) Affects Blood Levels of Other Medicines in Healthy People

NCT04059367
View directory record Official record
Conditions
Healthy Volunteers, Overweight, Obesity
Interventions
NNC9204-1177, Cocktail of 5 already approved drugs
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 60 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Sep 26, 2026, 3:34 PM EDT
Recruiting Phase 1 Interventional

An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis

NCT07665723
View directory record Official record
Conditions
Active Ulcerative Colitis
Interventions
Afimkibart, Caffeine, Warfarin, Omeprazole, Dextromethorphan, Midazolam, Vitamin K
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Chula Vista, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 26, 2026, 3:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy Subjects

NCT01402076
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Tasimelteon, Rosiglitazone, Midazolam
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 16, 2014 · Synced Sep 26, 2026, 3:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Drug Interaction Study With Lu AG06466 in Young Healthy Men

NCT04713254
View directory record Official record
Conditions
Healthy
Interventions
Lu AG06466, Midazolam, Metoprolol, Bupropion
Drug · Other
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Sep 26, 2026, 3:34 PM EDT